IASIS PHARMA played a pivotal role in the recognition of Chios Mastic at European and Global level as a unique herbal medicine with a wide range of beneficial but primarily therapeutic indications for the human.
As a result of IASIS PHARMA systematic and persistent effort, in close cooperation with the Faculty of Pharmacy of the University of Athens, the Chios Mastic Growers Association and its affiliated company Mediterra S.A., came the milestone recognition for Chios Mastic by the European Medicines Agency (EMA) as a herbal medicine after the proposal at the meeting that took place in London on August 7. The decision was unanimous and Chios Mastic was accepted to be included in the category of traditional herbal medicines. The pharmaceutical “monograph” of Chios Mastic includes two therapeutic indications:
- Mild Dyspeptic Disorders
- Skin Inflammations and Healing of Skin Lesions